等待開盤 09-20 09:30:00 美东时间
-0.050
-3.52%
Processa Pharmaceuticals press release (NASDAQ:PCSA): FQ2 GAAP EPS of -$1.01. Research and development expenses were $1.7 million, unchanged from the second quarter of 2023. The net loss for the secon...
08-28 22:23
Processa Pharma (NASDAQ:PCSA) reported quarterly losses of $(1.01) per share which beat the analyst consensus estimate of $(1.02) by 0.98 percent. This is a 49.5 percent increase over losses of $(2.00) per share from the
08-28 20:11
Processa Pharmaceuticals : Ngc-Cap Phase 1B Trial Demonstrated a Favorable Safe...
08-28 20:01
Phase 2 trial with NGC-Cap in breast cancer underway NGC-Cap Phase 1b trial dem...
08-28 20:00
Processa Pharmaceuticals Announces Positive Preclinical Data for Ngc-Iri
08-19 20:03
Processa Pharmaceuticals Inc: Studies Support Potential Benefit as an Improved ...
08-19 20:03
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts jus...
08-19 18:50
Processa Pharmaceuticals, Inc. : H.c. Wainwright Cuts Target Price to $6 From $8
08-19 18:10
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Processa Pharma (NASDAQ:PCSA) with a Buy and maintains $8 price target.
08-01 18:22
Shares of Merck & Co., Inc. (NYSE:MRK) fell sharply during Tuesday's sessio...
07-31 01:53